Clinical Trials Browser

NCT03967977 2026-04-17

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Phase 3 Active not recruiting

420 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04076059 2026-04-17

China ARCHES

Phase 3 Active not recruiting

180 enrolled 24 charts

Genitourinary

Metastatic Hormone Sensitive Prostate Cancer

NCT05794906 2026-04-17

ARASTEP

Phase 3 Active not recruiting

985 enrolled

Genitourinary

Biochemically Recurrent Prostate Cancer

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

855 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

Phase 3 Active not recruiting

60 enrolled 15 charts

Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT03528694 2026-04-14

POTOMAC

Phase 3 Active not recruiting

1,018 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04960709 2026-04-14

VOLGA

Phase 3 Active not recruiting

712 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT01575548 2026-04-13

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

Phase 3 Active not recruiting

129 enrolled 11 charts

Genitourinary

Carcinoma, Renal Cell

NCT01946204 2026-04-13

SPARTAN

Phase 3 Active not recruiting

1,207 enrolled 15 charts 2 FDA

Genitourinary

Prostatic Neoplasms

NCT02257736 2026-04-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 3 Active not recruiting

982 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT02489318 2026-04-13

TITAN

Phase 3 Active not recruiting

1,052 enrolled 13 charts 2 FDA

Genitourinary

Prostatic Neoplasms

NCT02531516 2026-04-13

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Phase 3 Active not recruiting

1,503 enrolled

Genitourinary

Prostatic Neoplasms

NCT03055013 2026-04-13

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Phase 3 Active not recruiting

819 enrolled 12 charts

Genitourinary

Carcinoma, Renal Cell

NCT03390504 2026-04-13

THOR

Phase 3 Active not recruiting

629 enrolled 32 charts 1 FDA

Genitourinary

Urothelial Cancer

NCT03748641 2026-04-13

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 2 FDA

Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03767244 2026-04-13

PROTEUS

Phase 3 Active not recruiting

2,517 enrolled

Genitourinary

Prostatic Neoplasms

NCT03775265 2026-04-13

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

475 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03793166 2026-04-13

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Phase 3 Active not recruiting

1,175 enrolled

Genitourinary

Carcinoma, Renal Cell, Lymphatic Metastasis

NCT04497844 2026-04-13

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 3 FDA

Genitourinary

Metastatic Castration-sensitive Prostate Cancer

NCT04557059 2026-04-13

PRIMORDIUM

Phase 3 Active not recruiting

693 enrolled

Genitourinary

Prostatic Neoplasms

NCT04579224 2026-04-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Phase 3 Active not recruiting

184 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04658862 2026-04-13

SunRISe-2

Phase 3 Active not recruiting

518 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05092958 2026-04-13

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Phase 3 Active not recruiting

654 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT05714202 2026-04-13

SunRISe-3

Phase 3 Active not recruiting

1,135 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06211764 2026-04-13

SunRISe-5

Phase 3 Active not recruiting

272 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05050084 2026-04-08

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Phase 3 Active not recruiting

2,050 enrolled

Genitourinary

Prostate Adenocarcinoma

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Phase 3 Active not recruiting

599 enrolled

Genitourinary

Prostatic Neoplasms

NCT05911295 2026-04-07

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Phase 3 Active not recruiting

412 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04513717 2026-04-03

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3 Active not recruiting

2,753 enrolled

Genitourinary

Prostatic Neoplasms

NCT05538663 2026-04-03

BRIDGE

Phase 3 Active not recruiting

870 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05863351 2026-04-03

Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

Phase 3 Active not recruiting

472 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04493853 2026-04-01

CAPItello-281

Phase 3 Active not recruiting

1,012 enrolled

Genitourinary

Prostatic Neoplasms

NCT03815643 2026-03-31

Avelumab Program Rollover Study

Phase 3 Active not recruiting

205 enrolled

GenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ovarian Neoplasms

NCT04660344 2026-03-27

IMvigor011

Phase 3 Active not recruiting

761 enrolled

Genitourinary

Muscle-invasive Bladder Cancer

NCT05678322 2026-03-25

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

Phase 3 Active not recruiting

26 enrolled 7 charts

Genitourinary

Prostatic Neoplasms

NCT03091660 2026-03-23

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

1,000 enrolled

Genitourinary

Stage 0 Bladder Urothelial Carcinoma

NCT04484818 2026-03-23

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Phase 3 Active not recruiting

27 enrolled

Genitourinary

Prostatic Neoplasms

NCT04689828 2026-03-23

PSMAfore

Phase 3 Active not recruiting

469 enrolled 11 charts 3 FDA

Genitourinary

Prostatic Neoplasms

NCT04637594 2026-03-20

IMAGINE

Phase 3 Active not recruiting

3 enrolled 6 charts

Genitourinary

Carcinoma, Transitional Cell

NCT00379340 2026-03-17

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Phase 3 Active not recruiting

395 enrolled 15 charts

Genitourinary

Wilms Tumor

NCT07477626 2026-03-17

RADVAN

Phase 3 Active not recruiting

374 enrolled

Genitourinary

Prostatic Neoplasms

NCT04452591 2026-03-16

BOND-003

Phase 3 Active not recruiting

190 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT03732677 2026-03-13

NIAGARA

Phase 3 Active not recruiting

1,063 enrolled 15 charts 3 FDA

Genitourinary

Urinary Bladder Neoplasms

NCT05884398 2026-03-12

LIBERTAS

Phase 3 Active not recruiting

420 enrolled

Genitourinary

Metastatic Castrate-sensitive Prostate Cancer

NCT04720157 2026-03-11

PSMAddition

Phase 3 Active not recruiting

1,145 enrolled

Genitourinary

Prostatic Neoplasms

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Phase 3 Active not recruiting

110 enrolled 12 charts

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05943106 2026-03-11

PATAPSCO

Phase 3 Active not recruiting

100 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07000149 2026-03-10

eVOLVE-RCC02

Phase 3 Active not recruiting

1,116 enrolled

Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT03036098 2026-03-06

CheckMate901

Phase 3 Active not recruiting

1,314 enrolled 23 charts 2 FDA

Genitourinary

Urothelial Cancer

NCT04586231 2026-03-05

MK-6482-011

Phase 3 Active not recruiting

747 enrolled

Genitourinary

Carcinoma, Renal Cell